The Prevention and Management of Distant Metastases in Women with Breast Cancer

REFERENCES

• Fisher B., Dignam J., Bryant J., Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl. Cancer Inst. 2001; 93(9)684–690
   PubMed Web of Science ®Google Scholar
• Boccardo F., Rubagotti A., Puntoni M., Guglielmini P., Amoroso D. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J. Clin. Oncol. 2005; 23(22)5138–5147, Epub July 11, 2005
   PubMed Web of Science ®Google Scholar
• Coombes R. C., Hall E., Gibson L. J., Paridaens R., Jassem J. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 2004; 350(11)1081–1092, published correction appears in N. Engl. J. Med. 2004 351, 23 2461
   PubMed Web of Science ®Google Scholar
• Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365(9453)60–62
   PubMed Web of Science ®Google Scholar
• Thürlimann B., Keshaviah A., Coates A. S., Mouridsen H., Mauriac L. Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 2005; 353(26)2747–2757
   PubMed Web of Science ®Google Scholar
• Weigelt B., Glas A. M., Wessels L. F.A., Witteveen A. T., Peterse J. L., van't Veer L. J. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc. Natl. Acad. Sci. 2003; 100(26)15901–15905
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Overview: Breast Cancer, http://www.cancer.org/docroot/CRI/content/CRI_2_2_1X_How_many_people_get_breast_cancer_5.asp Available at: Accessed November 14, 2005
   Google Scholar
• Cianfrocca M., Goldstein L. J. Prognostic and predictive factors in early-stage breast cancer. Oncologist 2004; 9(6)606–616
   PubMed Web of Science ®Google Scholar
• Lamerato L., Havstad S., Gandhi S., Jones D., Chlebowski R. Breast cancer recurrence and related mortality in US pts with early breast cancer. 2005 ASCO Annual Meeting Proceedings (post-meeting edition). J. Clin. Oncol. 2005; 25: 62S, (Suppl. 16), (Abstr. 738)
   Google Scholar
• Lê M. G., Arriagada R., Spielmann M., Guinebretière J. M., Rochard F. Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma. Cancer 2002; 94(11)2813–2820
   PubMed Web of Science ®Google Scholar
• Citron M. L., Berry D. A., Cirrincione C., Hudis C., Winer E. P. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 2003; 21(8)1431–1439
   PubMed Web of Science ®Google Scholar
• Sorensen S. V., Brown R., Benedict A., Flood E., Revicki D. Patient-rated utilities in postmenopausal early breast cancer (EBC): a cross-country comparison. Value Health 2004; 7(6)641–642
   Web of Science ®Google Scholar
• Parker B., Sukumar S. Distant metastasis in breast cancer: molecular mechanisms and therapeutic targets. Cancer Biol. Ther. 2003; 2(1)14–21
   PubMed Web of Science ®Google Scholar
• Schmidt-Kittler O., Ragg T., Daskalakis A., Granzow M., Ahr A. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc. Natl. Acad. Sci. USA 2003; 100(13)7737–7742
   PubMed Web of Science ®Google Scholar
• Goldstein N. S., Vicini F. A., Hunter S., Goldstein N. S., Vicini F. A. Molecular clonality determination of ipsilateral recurrence of invasive breast carcinomas after breast-conserving therapy: comparison with clinical and biologic factors. Am. J. Clin. Pathol. 2005; 123(5)679–689
   PubMed Web of Science ®Google Scholar
• Westenend P. J., Meurs C. J.C., Damhuis R. A.M. Tumour size and vascular invasion predict distant metastasis in stage I breast cancer. Grade distinguishes early and late metastasis. J. Clin. Pathol. 2005; 58(2)196–201
   PubMed Web of Science ®Google Scholar
• Braun S., Vogl F. D., Naume B., Janni W., Osborne M. P. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 2005; 353(8)793–802
   PubMed Web of Science ®Google Scholar
• Lawrence G., Pritchard M. G., Kearins O., Casey M. An analysis of breast cancer recurrences for screen detected and symptomatic breast cancers diagnosed in the West Midlands in 1996 and 1997. Breast Cancer Res. Treat. 2005; 94: S211, (Suppl. 1) (Abstr. 5019)
   Web of Science ®Google Scholar
• Thames H. D., Buchholz T. A., Smith C. D. Frequency of first metastatic events in breast cancer: implications for sequencing of systemic and local-regional treatment. J. Clin. Oncol. 1999; 17: 2649–2658
   PubMed Web of Science ®Google Scholar
• Bijker N., Peterse J. L., Duchateau L., Julien J. P., Fentiman I. S. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J. Clin. Oncol. 2001; 19(8)2263–2271
   PubMed Web of Science ®Google Scholar
• Vicini F. A., Kestin L., Huang R., Martinez A. Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy?. Cancer 2003; 97(4)910–919
   PubMed Web of Science ®Google Scholar
• Baum M., Demicheli R., Hrushesky W., Retsky M. Does surgery unfavourably perturb the “natural history” of early breast cancer by accelerating the appearance of distant metastases?. Eur. J. Cancer 2005; 41(4)508–515
   PubMed Web of Science ®Google Scholar
• Saphner T., Tormey D. C., Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J. Clin. Oncol. 1996; 14(10)2738–2746
   PubMed Web of Science ®Google Scholar
• Hortobagyi G. N., Kau S. W., Buzdar A. U., Theriault R. L., Booser D. J., Gwyn K., Valero V. UT M.D. Anderson Cancer Center, Houston, TX. What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis? 2004 ASCO Annual Meeting Proceedings (post-meeting edition). J. Clin. Oncol. 2004; 22, (Suppl. 14)(Abstr. 585)
   Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365(9472)1687–1717
   PubMed Web of Science ®Google Scholar
• Glück S. Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin. Oncologist 2005; 10(10)780–791
   PubMed Web of Science ®Google Scholar
• Bonadonna G., Valagussa P., Moliterni A., Zambetti M., Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N. Engl. J. Med. 1995; 332(14)901–906
   PubMed Web of Science ®Google Scholar
• Bonadonna G., Moliterni A., Zambetti M., Daidone M. G., Pilotti S., Gianni L., Valagussa P. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005; 330(7485)217
   PubMed Web of Science ®Google Scholar
• Fisher B., Dignam J., Mamounas E. P., Costantino J. P., Wickerham D. L. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J. Clin. Oncol. 1996; 14(7) 1982–1992
   PubMed Web of Science ®Google Scholar
• Bonadonna G., Brusamolino E., Valagussa P., Rossi A., Brugnatelli L. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N. Engl. J. Med. 1976; 294(8)405–410
   PubMed Web of Science ®Google Scholar
• Goss P. E., Ingle J. N., Martino S., Robert N. J., Muss H. B. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl. Cancer Inst. 2005; 97(17)1262–1271
   PubMed Web of Science ®Google Scholar
• Winer E. P., Hudis C., Burstein H. J., Wolff A. C., Pritchard K. I. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol. 2005; 23(3)619–629
   PubMed Web of Science ®Google Scholar
• Buzdar A. U.; on behalf of the ATAC Trialists' group. Impact of adjuvant chemotherapy prior to endocrine therapy: 68 month results from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. 2005 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 2005; 23: 309, (Suppl. 16), (Abstr. 608)
   Google Scholar
• Anastrozole [package insert]. AstraZeneca Pharmaceuticals LP, Wilmington, DE 2002
   Google Scholar
• Jakesz R., Jonat W., Gnant M., Mittlboeck M., Greil R. On behalf of the ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366(9484)455–462
   PubMed Web of Science ®Google Scholar
• Jelovac D., Macedo L., Handratta V., Long B. J., Goloubeva O. G., Ingle J. N., Brodie A. M. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. Clin. Cancer Res. 2004; 10(21)7375–7381
   PubMed Web of Science ®Google Scholar
• Geisler J., Haynes B., Anker G., Dowsett M., Lønning P. E. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Clin. Oncol. 2002; 20(3)751–757
   PubMed Web of Science ®Google Scholar
• Rose C., Vtoraya O., Pluzanska A., Davidson N., Gershanovich M. An open randomised trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur. J. Cancer 2003; 39(16)2318–2327
   PubMed Web of Science ®Google Scholar
• Mauriac L., Keshaviah A., Debled M., Mouridsen H., Forbes J. Predictors of early relapse in postmenopausal women with hormone receptor positive breast cancer in the BIG 1-98 trial. Ann. Oncol. Feb 14, 2007, Epub ahead of print
   PubMedGoogle Scholar
• Coombes R. C., Paridaens R., Jassem J. First mature analysis of the Intergroup Exemestane Study. J. Clin. Oncol. 2006; 24: 933s, (Suppl. 18) (Abstr. LBA 527)
   Web of Science ®Google Scholar
• Pritchard K. I. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen. J. Clin. Oncol. 2005; 23(22)4850–4852
   PubMed Web of Science ®Google Scholar
• Houghton J.; on behalf of the ATAC Trialists' Group. Using anastrozole as initial adjuvant treatment prevents early recurrences and reduces adverse events: updated data from the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial. 2005 ASCO Annual Meeting Proceedings (post-meeting edition). J. Clin. Oncol. 2005; 23: 24S, (Suppl. 16) (Abstr. 582)
   PubMed Web of Science ®Google Scholar
• Baum M., Cuzick J., Howell A., Buzdar A., Demicheli R., Greco M., Retsky M., Hrushesky B.; on behalf of the ATAC Trialists' Group and the Milan Institute. An exploration of relapse data by hazard rate as a means of developing biological insights into the natural history and treatment of breast cancer: data from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial and the Milan Institute database. 2005 ASCO Annual Meeting Proceedings (post-meeting edition). J. Clin. Oncol. 2005; 25: 31S, (Suppl. 16) (Abstr. 612)
   Google Scholar
• Houghton J.; on behalf of the ATAC Trialists' Group. Intial adjuvant therapy with ANA (S) reduced rates of early breast cancer recurrent and adverse events compared with TAM (T)-data reported on behalf of the ATAC (‘Arimidex’, TAM, Alone or in Cbomination) Trialists' group. Ann. Oncol. 2006; 17: ix93, (Suppl. 9) (Abstr. 243PD)
   Google Scholar
• Jung J., Hwang G., Lee Y., Park H., Yang Y. Pamidronate as adjuvant treatment for prevention of bone metastasis in breast cancer. 2005 ASCO Annual Meeting Proceedings (post-meeting edition). J. Clin. Oncol. 2005; 23: 99S, (Suppl. 16) (Abstr. 888)
   Web of Science ®Google Scholar
• Theriault R. L., Lipton A., Hortobagyi G. N., Leff R., Glück S. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J. Clin. Oncol. 1999; 17(3)846–854
   PubMed Web of Science ®Google Scholar
• López-Guerrero J. A., Llombart-Cussac A., Noguera R., Navarro S., Pellin A., Almenar S., Vazquez-Alvadalejo C., Llombart-Bosch A. HER2 amplification in recurrent breast cancer following breast-conserving therapy correlates with distant metastasis and poor survival. Int. J. Cancer. 2006; 118(7)1743–1749, Epub October 10, 2005
   PubMed Web of Science ®Google Scholar
• Romond E. H., Perez E. A., Bryant J., Suman V. J., Geyer C. E., Jr. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005; 353(16)1673–1684
   PubMed Web of Science ®Google Scholar
• Romond E. H. Breast Cancer Update, www.breastcancerupdate.com/bcu2005/6/romond.htm. Available at: Accessed October 31, 2005
   Google Scholar
• Cavenee W. K., White R. L. The genetic basis of cancer. Sci. Am. 1995; 272(3)72–79
   PubMed Web of Science ®Google Scholar
• Rugo H. S. Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 2004; 9: 43–49, (Suppl. 1)
   PubMed Web of Science ®Google Scholar
• The CAT study: atamestane plus toremifene versus letrozole in advanced breast cancer, http://www.clinicaltrials.gov/ct/gui/show/NCT00097344 Available at: ClinicalTrials.gov 2005 Accessed June 30, 2005
   Google Scholar
• Sierra A. Metastases and their microenvironments: linking pathogenesis and therapy. Drug Resist. Update. 2005; 8(4)247–257
   PubMed Web of Science ®Google Scholar
• Malek K., Fink A. K., Thwin S. S., Gurwitz J., Ganz P. A., Silliman R. A. The relationship among physicians' specialty, perceptions of the risks and benefits of adjuvant tamoxifen therapy, and its recommendation in older patients with breast cancer. Med. Care 2004; 42(7)700–706
   PubMed Web of Science ®Google Scholar
• Jakesz R., Samonigg H., Greil R., Gnant M., Schmid M., Kwasny W., Kubista E., Mlineritsch B., Tausch C., Stierer M.; on behalf of the ABCSG. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). 2005 ASCO Annual Meeting Proceedings (post-meeting edition). J. Clin. Oncol. 2005; 23: 10S, (Suppl. 16) (Abstr. 526)
   Web of Science ®Google Scholar
• Mansell J., Moneypenny I. J., Skene A. I. Predictors of early recurrence in postmenopausal women with operable breast cancer. Breast Cancer Research and Treatment. 2006; 100, (Suppl. 1). (Abstr. 2091)
   Web of Science ®Google Scholar